Comparison of histopathological outcomes HPV testing in urine and cervical samples.

Objective: The goal of cervical screening is to identify and treat high grade cervical intraepithelial neoplasia (HSIL), in order to reduce the incidence of the cancer. The objective of this investigation was to analyze the sensitivity and detection rate of HSIL in urine samples from those who tested status for HPV, as well as to assess and contrast the histopathological findings of HPV-positive individuals in cervical and urine specimens. Materials and Methods: This study comprised 151 patients who had previously tested positive for HPV in their cervical samples. The commercial real-time PCR techniques via Roche Cobas Test were used for identification and genotyping HPV in urine specimens. The examination of cytological and histological samples evaluated according to Bethesda criteria and LAST PROJECT. Results: HPV types 16, 18, and/or together OHR 100% and 80% were present in HSIL cases in cervical and urine samples, respectively. Urine samples had a sensitivity of 85.7% and a specificity of 32.7% for detecting HSIL/CIN2 lesions, and a sensitivity of 83.3% and a specificity of 36.1% for detecting HSIL/CIN3 lesions. Individuals with HPV-positive urine had a sensitivity and specificity of 74% and 46.2%, respectively, for identifying persistent infection. Conclusion: HPV positivity was not detected in all urine samples due to the lack of a standardized tool. However, urine HR-HPV screening has a high sensitivity to determining the presence of high-grade lesions. Furthermore, urine HR-HPV screening may be used as a predictive tool for the persistence of HPV infection.